A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults



Status:Active, not recruiting
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:9/5/2018
Start Date:October 26, 2010
End Date:June 30, 2019

Use our guide to learn which trials are right for you!

A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults

ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel
group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected
antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to
receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an
investigator selected background regimen consisting of at least one fully active agent plus
no more than one second single agent which may or may not be active. Antiviral activity,
safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.

ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel
group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected
antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to
receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an
investigator selected background regimen consisting of at least one fully active agent plus
no more than one second single agent which may or may not be active. Antiviral activity,
safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.

Subjects must have documented genotypic or phenotypic resistance to at least one member of
each of at least two antiretroviral therapy (ART) drug classes [nucleoside/nucleotide reverse
transcriptase inhibitor (N[t]RTI), non-nucleoside reverse transcriptase inhibitor (NNRTI),
protease inhibitor (PI), fusion inhibitor (T20), or entry inhibitor (chemokine receptor 5
[CCR5] antagonist)].

The primary analysis will take place after the last subject completes 48 weeks on therapy. An
additional data cut and analysis will be conducted after the last subject completes 24 weeks
on therapy.

Subjects randomized to GSK1349572 who successfully complete Week 48 will continue to received
GSK1349572 until either it is locally available, until they no longer derive clinical
benefit, until they meet a protocol-defined reason for discontinuation, or until development
of the compound is terminated.

ViiV Healthcare is the sponsor of this study, and GlaxoSmithKline is in the process of
updating systems to reflect the change in sponsorship

Inclusion Criteria:

- Antiretroviral therapy (ART)-experienced, Human Immunodeficiency Virus (HIV) -1
infected adults at least 18 years of age.

- Women capable of becoming pregnant must use appropriate contraception during the study
(as defined by the protocol).

- HIV-1 infection as documented by HIV-1 RNA >400 copies/mL (c/mL) at Screening and with
at least one consecutive HIV-1 RNA >400 c/mL within the four months prior to Screening
(unless the Screening HIV-1 RNA is > 1000 c/mL where no additional plasma HIV-1 RNA
assessment is needed).

- Have documented resistance (via Screening resistance test) to two or more different
classes of antiretroviral agents. For subjects off ART for at least one month, if
Screening resistance results provide a fully active agent and do not show two class
resistance then historical resistance results from the subject's most recent
resistance testing may be used, following consultation with the study virologist and
/or medical monitor.

- Integrase inhibitor (INI)-naïve, defined as no prior exposure to any INI (e.g. RAL,
elvitegravir, or GSK1349572).

- Able to provide written informed consent prior to Screening.

- French subjects: In France, subjects will be eligible for inclusion in this study only
if either affiliated to or a beneficiary of a social security category.

Exclusion Criteria:

- Screening resistance test result indicates no fully active antiviral agents are
available for design of the background regimen.

- Subject-virus does not yield results using genotype/phenotype/tropism at Screening
(assay data is essential for eligibility determination).

- Women who are breastfeeding.

- Any evidence of an active AIDS-defining condition (except cutaneous Kaposi's sarcoma
not requiring systemic therapy or CD4+ <200c/mm3).

- Subjects with moderate to severe hepatic impairment as defined by Child-Pugh
classification.

- Recent history (less than or equal to 3 months) of upper or lower gastrointestinal
bleed, with the exception of anal or rectal bleeding.

- Anticipated need for hepatitis C therapy during the study.

- History or presence of allergy or intolerance to the study drugs or their components
or drugs of their class.

- History of malignancy within the past 5 years or ongoing malignancy other than
cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous
squamous cell carcinoma; other localized malignancies require agreement between the
investigator and study medical monitor for inclusion of the subject.

- Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to Screening.

- Treatment with any of the following agents within 28 days of Screening: radiation
therapy, cytotoxic chemotherapeutic agents, any immunomodulator.

- Treatment with any agent, other than licensed ART, which has documented activity
against HIV-1 in vitro within 28 days of first dose of investigational product.

- Exposure to an experimental drug and/or experimental vaccine within either 28 days, 5
half-lives of the test agent, or twice the duration of the biological effect of the
experimental test agent - whichever is longer, prior to the first dose of IP.

- French subjects recruited at sites in France will be excluded if the subject has
participated in any study using an investigational drug and/or vaccine within 60 days
or 5 half-lives, or twice the duration of the biological effect of the experimental
drug or vaccine - whichever is longer - prior to screening for the study or the
subject plans to participate simultaneously in another clinical study.

- Any acute or verified Grade 4 laboratory abnormality.

- Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN).

- ALT greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN
(with >35% direct bilirubin).
We found this trial at
61
sites
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Akron, Ohio 44313
?
mi
from
Akron, OH
Click here to add this to my saved trials
Allentown, Pennsylvania 18102
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Annandale, Virginia 22003
?
mi
from
Annandale, VA
Click here to add this to my saved trials
Augusta, Georgia 30909
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Bakersfield, California 93309
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Birmingham, Alabama 35249
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bronx, New York 10461
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charleston, South Carolina 29425
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28203
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45229
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Ciudad Autonoma de Buenos Aires, Buenos Aires
?
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Dallas, Texas 75230
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Daytona Beach, Florida 32117
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
Fort Lauderdale, Florida 33308
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Fort Pierce, Florida 34982
?
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Greenville, North Carolina 27858
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Hillsborough, New Jersey 08844
?
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Iowa City, Iowa 52242
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Kansas City, Missouri 64128
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lansing, Michigan 48917
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Long Beach, California 90813
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Longview, Texas 75605
?
mi
from
Longview, TX
Click here to add this to my saved trials
Los Angeles, California 90025
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Maywood, Illinois 60153
?
mi
from
Maywood, IL
Click here to add this to my saved trials
Miami Beach, Florida 33140
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Neptune, New Jersey
?
mi
from
Neptune, NJ
Click here to add this to my saved trials
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10032
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, New Jersey 07112
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Norwalk, Connecticut 06850
?
mi
from
Norwalk, CT
Click here to add this to my saved trials
Oakland, California 94611
?
mi
from
Oakland, CA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73112
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Omaha, Nebraska 68131
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85012
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Portland, Oregon 97227
?
mi
from
Portland, OR
Click here to add this to my saved trials
Providence, Rhode Island 02903
?
mi
from
Providence, RI
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Antonio, Texas 78258
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Savannah, Georgia 31405
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Seattle, Washington 98109
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Spokane, Washington 99208
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Springfield, Massachusetts 01199
?
mi
from
Springfield, MA
Click here to add this to my saved trials
Springfield, Virginia 22151
?
mi
from
Springfield, VA
Click here to add this to my saved trials
Tulsa, Oklahoma 74105
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Valhalla, New York 10595
?
mi
from
Valhalla, NY
Click here to add this to my saved trials
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials
West Palm Beach, Florida 33409
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Wilton Manors, Florida 33305
?
mi
from
Wilton Manors, FL
Click here to add this to my saved trials